Hinge Bio is a development-stage biotechnology company led by CEO Barry Selick, Ph.D., that leverages its proprietary GEM-DIMER™ platform to design multivalent, multispecific antibody-based therapeutics. The GEM-DIMER technology enables creation of antibody therapeutics that bind targets cooperatively to enhance biological activity and functionality. The company is advancing a lead product candidate, HB2198, intended for patients living with Systemic Lupus Erythematosus (Lupus). Hinge Bio plans to use new funding to support entry of HB2198 into a Phase 1 clinical trial and to develop additional therapeutics from the GEM-DIMER platform. The company is based in Burlingame, CA. The article describes Hinge Bio as development-stage and does not disclose operating metrics beyond the financing.

Total raised

$30M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2025